Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (mCRC).Celine Hoyek, Tanios Bekaii‐Saab, Mitesh J. Borad et al.|Journal of Clinical Oncology|2025Cited by 4
Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC).Celine Hoyek, Tanios Bekaii‐Saab, Angelo Pirozzi et al.|Journal of Clinical Oncology|2025Cited by 0
Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).Oluseyi Abidoye, Daniel H. Ahn, Anina Peersen et al.|Journal of Clinical Oncology|2025Cited by 0
328P Time toxicity (TT) associated with first-line treatment (1L) in patients (pts) with advanced biliary tract cancer (aBTC)Naohiro Okano, Mitesh J. Borad, Anna Virginia Adriana Pirozzi et al.|Annals of Oncology|2025Cited by 0
444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancerOluseyi Abidoye, Tanios Bekaii‐Saab, Heidi Kosiorek et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0